Home·Stocks·ENOV

ENOV

NYSE

Enovis CORP

Technology · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed
$1.4B
2021
$1.6B
2022
$1.7B
2023
$2.1B
2024
$2.2B
2025

Snapshot

SEC EDGAR · FY 2025-12-31
Revenue$2.2B
Net Income$-1.2B
Gross Profit$1.3B
Oper Income$-1.1B
EPS (dil)$-20.75
Rev/sh$39.05
FCF/sh$0.35
Book/sh$25.92
Gross M59.8%
Oper M-50.0%
Profit M-52.7%
FCF M0.9%
ROE-79.3%
ROA-30.9%
ROIC-41.1%
R&D/Rev5.4%
Rev Y/Y6.7%
Rev 3Y CAGR12.9%
EPS Y/Y-39.0%
EPS 3Y CAGR
FCF 3Y CAGR
Payout0%
Div/sh
Shs Chg Y/Y+3.2%
Current Ratio2.02
Quick Ratio1.04
Debt/Eq0.89
Int Coverage-32.3×
Net Debt$1.3B
Total Debt$1.3B
Cash & Eq$36.4M
Total Assets$3.8B
Oper CF$217.3M
Capex$197.4M
Free CF$19.9M
Buybacks$3.5M
Equity$1.5B
Liabilities$2.3B
Shs Outstand0.06B
SectorTechnology
🔒 P/E
🔒 Fwd P/E
🔒 P/S
🔒 P/B
🔒 Market Cap
🔒 Div Yield
🔒 52W Range
🔒 Beta
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.

Financials — annual

SEC EDGAR · last 5 FY
USDFY2021FY2022FY2023FY2024FY2025
Revenue$1.4B$1.6B$1.7B$2.1B$2.2B
Gross Profit$777.7M$869.4M$990.8M$1.2B$1.3B
Operating Income$-62.8M$-71.2M$-65.7M$-775.7M$-1.1B
Net Income$76.3M$-11.8M$-32.7M$-824.8M$-1.2B
Diluted EPS$1.40$-0.25$-0.61$-14.93$-20.75
Operating Cash Flow$356.1M$-55.9M$135.0M$113.5M$217.3M
Free Cash Flow$251.9M$-161.3M$12.8M$-67.2M$19.9M
COMMUNITY · $ENOV0 theses
POST YOUR TAKE →

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.